Loading
Life sciences · Journal article
Apu Journal · October 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
We describe the case of a 78- year- old man with metastatic hormone- sensitive prostate adenocarcinoma who was diagnosed with a metachronous right testicular seminoma during follow- up. He initially presented with low back pain, weight loss, and a PSA level of 909 ng/mL. Prostate biopsy revealed a Gleason 9 (4+5)(4+5) adenocarcinoma with extensive osseous metastases and pelvic and interatocoval nodal involvement. He initiated androgen deprivation therapy with leuprorelin (preceded by bicalutamide) combined with apalutamide, achieving good biochemical and clinical response. At 12 months, progression of the interatocoval lymphadenopathy was observed, and he underwent palliative radiotherapy. At month 14, evaluation of right testicular enlargement revealed a mass subsequently confirmed as seminoma (pT1b, R0) following radical orchiectomy. Post- radiotherapy and post- orchiectomy computed tomography (CT) demonstrated significant regression of the retroperitoneal lymphadenopathy. This case underscores the importance of considering second primary malignancies during prostate oncologic follow- up, particularly when new clinical findings are not fully explained by the underlying disease.